期刊
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
卷 -, 期 -, 页码 56-61出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/asheducation-2010.1.56
关键词
-
In younger patients with acute myeloid leukemia (AML), initial treatment has provided very good control of the disease. Induction therapy has used combination chemotherapy, with anthracycline and cytarabine as the foundation. Recent trials support dose intensification of anthracycline in induction. Intensive postremission therapy further contributes to improving survival. The addition of targeted therapy with gemtuzumab ozogamicin to standard therapy has not improved on these outcomes. Newer agents targeted to specific molecular abnormalities or survival mechanisms in the leukemic cell are being studied as future additions to the current standard therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据